Cover Image
市場調查報告書

特發性血小板減少紫斑症(免疫性血小板缺乏紫斑症):開發平台分析

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 237879
出版日期 內容資訊 英文 108 Pages
訂單完成後即時交付
價格
Back to Top
特發性血小板減少紫斑症(免疫性血小板缺乏紫斑症):開發平台分析 Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline Review, H2 2016
出版日期: 2016年08月24日 內容資訊: 英文 108 Pages
簡介

特發性血小板減少紫斑症(ITP),是血小板數減少,變得容易出血的疾病。這個疾病的症狀有刀傷出血難停,鼻子的突發性出血,血尿和血便,牙齦的出血,倦怠感等。ITP的代表性治療方法,有腎上腺皮質荷爾蒙(皮質類固醇)和免疫抑制劑的投藥。

本報告提供全球開發平台中的特發性血小板減少紫斑症(免疫性血小板缺乏紫斑症)治療藥概要,目前開發平台狀況和最新趨勢,後期階段及中止的計劃的資訊,主要企業及開發中產品評測等,為您概述為以下內容。

簡介

  • 調查範圍

特發性血小板減少紫斑症(免疫性血小板缺乏紫斑症)概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

特發性血小板減少紫斑症(免疫性血小板缺乏紫斑症):企業開發中的治療藥

特發性血小板減少紫斑症(免疫性血小板缺乏紫斑症):大學/機關研究中的治療藥

特發性血小板減少紫斑症(免疫性血小板缺乏紫斑症):開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

特發性血小板減少紫斑症(免疫性血小板缺乏紫斑症):企業開發中的產品

特發性血小板減少紫斑症(免疫性血小板缺乏紫斑症):大學/機關研究中的產品

特發性血小板減少紫斑症(免疫性血小板缺乏紫斑症)的開發治療藥的企業

  • 3SBio Inc.
  • Amgen Inc.
  • Baxalta Incorporated
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Eisai
  • Hansa Medical AB
  • Immunomedics, Inc.
  • Intas Pharmaceuticals Ltd.
  • Jiangsu Hengrui Medicine Co., Ltd.
  • Merck & Co., Inc.
  • Momenta Pharmaceuticals, Inc.
  • Novartis AG
  • Pfizer Inc.
  • PhytoHealth Corporation
  • Protalex, Inc.
  • Rigel Pharmaceuticals, Inc.

特發性血小板減少紫斑症(免疫性血小板缺乏紫斑症):治療藥的評估

  • 單劑產品
  • 各標的
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • 自體免疫疾病、發炎抑制劑
  • avatrombopag
  • BI-655064
  • BMS-986004
  • eltrombopag olamine
  • eltrombopag olamine
  • fostamatinib disodium
  • GL-2045
  • GSK-2285921
  • Hetrombopag Olamine
  • MK-8723
  • PBF-1509
  • PHN-013
  • PRTX-100
  • 自體免疫疾病免疫球蛋白G抑制重組的酵素
  • romiplostim
  • romiplostim 生技仿製藥
  • SM-101
  • thrombopoietin
  • veltuzumab

特發性血小板減少紫斑症(免疫性血小板缺乏紫斑症):最近的開發平台趨勢

特發性血小板減少紫斑症(免疫性血小板缺乏紫斑症):暫停中的計劃

特發性血小板減少紫斑症(免疫性血小板缺乏紫斑症):開發中止的產品

特發性血小板減少紫斑症(免疫性血小板缺乏紫斑症):產品開發里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8392IDB

Summary

Global Markets Direct's, 'Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline Review, H2 2016', provides an overview of the Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)
  • The report reviews pipeline therapeutics for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) therapeutics and enlists all their major and minor projects
  • The report assesses Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Overview
  • Therapeutics Development
    • Pipeline Products for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Overview
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Therapeutics under Development by Companies
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Products under Development by Companies
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Companies Involved in Therapeutics Development
    • 3SBio Inc.
    • AkaRx Inc
    • Amgen Inc.
    • arGEN-X BV
    • Boehringer Ingelheim GmbH
    • Bristol-Myers Squibb Company
    • Genosco
    • Hansa Medical AB
    • Immunomedics, Inc.
    • Intas Pharmaceuticals Ltd.
    • Jiangsu Hengrui Medicine Co., Ltd.
    • Merck & Co., Inc.
    • Momenta Pharmaceuticals, Inc.
    • Novartis AG
    • Pfizer Inc.
    • PhytoHealth Corporation
    • Protalex, Inc.
    • Rigel Pharmaceuticals, Inc.
    • Shire Plc
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • Antibody for Autoimmune Disorders and Inflammation - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ARGX-113 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • avatrombopag - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BI-655064 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BMS-986004 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • eltrombopag olamine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • eltrombopag olamine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • fostamatinib disodium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GL-2045 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GSK-2285921 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Hetrombopag Olamine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • M-281 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MK-8723 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PHN-013 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PRTX-100 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Enzyme to Inhibit Immunoglobulin G for Autoimmune Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • romiplostim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • romiplostim biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SKIO-703 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SM-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • thrombopoietin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • veltuzumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Dormant Projects
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Discontinued Products
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Product Development Milestones
    • Featured News & Press Releases
      • Jun 10, 2016: Novartis highlights long-term safety data of Revolade in adults with chronic immune thrombocytopenia, a rare blood disorder
      • May 19, 2016: Amgen Highlights Data on Nplate (romiplostim) at 21st Congress Of The European Hematology Association
      • Apr 07, 2016: Novartis receives EU approval for Revolade as first-in-class therapy for children aged 1 year and above with chronic ITP
      • Apr 01, 2016: Rigel Completes Enrollment of FIT Phase 3 Program for Fostamatinib in ITP
      • Jan 29, 2016: CHMP adopts extension to existing therapeutic indication for eltrombopag
      • Jan 28, 2016: Rigel Completes Enrollment of First Phase 3 Study of Fostamatinib in ITP
      • Jan 07, 2016: Rigel Reviews Recent Progress and Announces Presentation at the 34th Annual J.P. Morgan Healthcare Conference in San Francisco
      • Sep 08, 2015: Rigel Granted Orphan Drug Designation for Fostamatinib in ITP
      • Jun 11, 2015: Novartis gains FDA approval for Promacta providing new option for children, ages 6 and older, with chronic ITP, a rare blood disorder
      • Feb 06, 2015: GSK announces EU regulatory submission seeking additional indication for eltrombopag (Revolade)
      • Dec 22, 2014: GSK announces US regulatory submission seeking additional indication for eltrombopag (Promacta)
      • Jul 16, 2014: Rigel Initiates Phase 3 Studies of Fostamatinib in ITP
      • Oct 31, 2013: Kyowa Hakko Kirin Announces Launch Of Nplate In Taiwan
      • Oct 24, 2013: Rigel Provides Update On Oral SYK Inhibitor Fostamatinib
      • Jul 24, 2013: NICE says yes to blood disorder treatment in final guidance
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by 3SBio Inc., H2 2016
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by AkaRx Inc, H2 2016
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Amgen Inc., H2 2016
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by arGEN-X BV, H2 2016
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Boehringer Ingelheim GmbH, H2 2016
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Bristol-Myers Squibb Company, H2 2016
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Genosco, H2 2016
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Hansa Medical AB, H2 2016
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Immunomedics, Inc., H2 2016
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Intas Pharmaceuticals Ltd., H2 2016
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H2 2016
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Merck & Co., Inc., H2 2016
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Momenta Pharmaceuticals, Inc., H2 2016
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Novartis AG, H2 2016
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Pfizer Inc., H2 2016
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by PhytoHealth Corporation, H2 2016
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Protalex, Inc., H2 2016
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Rigel Pharmaceuticals, Inc., H2 2016
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Shire Plc, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Dormant Projects, H2 2016
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top